GGrantIndex
Sort

64,565 grants matching drug discovery

Optimization of a Combined Drug and Delivery Device for Treatment of Cyanide Poisoning

$505,514
Steven E Patterson · University Of Minnesota · U01 · FY2020 · NS

Microtubule Dynamics and Mitotic Mechanism

$505,486
Timothy J Mitchison · Harvard Medical School · R01 · FY2009 · GM

Identification of Old-Age-Associated Alzheimer's Disease Drug Targets

$505,457
David R Schubert · Salk Institute For Biological Studies · R01 · FY2018 · AG

Novel strategies for induction of aging in human iPSC-derived lineages towards improved models of late-onset diseases

$505,452
Lorenz P. Studer · Sloan-Kettering Inst Can Research · R01 · FY2021 · AG

ANTI-ORTHOPOXVIRUS DRUG DISCOVERY AND DEVELOPMENT

$505,447
Auburn University At Auburn · U01 · FY2003 · AI

The Center for Therapeutic Targeting of EWS-oncoproteins

$505,427
Kimberly Stegmaier · Dana-Farber Cancer Inst · U54 · FY2022 · CA

Reposition and Optimization of Deferiprone for Breast Cancer Therapy

$505,386
Adegboyega Oyelere · Georgia Institute Of Technology · R01 · FY2021 · CA

ITM 2.0: Advancing Translational Science in Metropolitan Chicago

$505,343
Julian Solway · University Of Chicago · UL1 · FY2018 · TR

Chemoproteomic methods for serine hydrolase inhibitor development

$505,322
Benjamin F Cravatt · Scripps Research Institute, The · R01 · FY2015 · DA

PHYSIOLOGY AND GENETICS OF GDNF FAMILY OF LIGANDS

$505,321
Jeffrey D Milbrandt · Washington University · R01 · FY2015 · AG

Gonococci: Genetics of Resistance to PMN Proteins

$505,297
William Maurice Shafer · Emory University · R01 · FY2021 · AI

Drug Discovery for Fatty Acid Synthase in Oncology

$505,254
Jeffrey W Smith · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2011 · CA

RESEARCH PROJECT 4: Biomarker-based Evaluation of Human Interventions

$505,241
Thomas A Kensler · Johns Hopkins University · P01 · FY2009 · ES

Long-lived mice and species as test beds for drug and pathway discovery

$505,220
Richard A. Miller · California Pacific Med Ctr Res Institute · U19 · FY2020 · AG

JHU- Optimal regimen development on a Ribosome inhibitor backbone.

$505,143
Eric L Nuermberger · Global Alliance For Tb Drug Development · U19 · FY2020 · AI

Product Development Core

$505,023
Julian P Whitelegge · University Of California Los Angeles · U19 · FY2015 · AI

Core F: Biomarker

$505,011
Celeste Marie Karch · Washington University · P30 · FY2023 · AG

Chemoproteomic methods for serine hydrolase inhibitor development

$504,995
Benjamin F Cravatt · Scripps Research Institute, The · R01 · FY2012 · DA

DISCOVERY OF IN VIVO CHEMICAL PROBES FOR POLYCOMB CBX DOMAINS

$504,942
Stephen Vernon Frye · Univ Of North Carolina Chapel Hill · R01 · FY2019 · CA

Otitis Media-associated pneumococcal genes

$504,887
Dennis W. Metzger · Albany Medical College · R01 · FY2010 · DC

Training program in cancer pharmacology

$504,858
Ian Alexander Blair · University Of Pennsylvania · R25 · FY2013 · CA

Estrogen receptor mediated reprogramming of prostate in BPH

$504,821
Paul S Cooke · University Of Florida · R01 · FY2021 · DK

USP7 inhibitors for the treatment of multiple myeloma

$504,721
Sara J Buhrlage · Dana-Farber Cancer Inst · R01 · FY2017 · CA

USP7 inhibitors for the treatment of multiple myeloma

$504,721
Sara J Buhrlage · Dana-Farber Cancer Inst · R01 · FY2018 · CA

Stage-specific roles for Zmiz1 in Notch-dependent steps of early T-cell development

$504,685
Mark Y Chiang · University Of Michigan At Ann Arbor · R01 · FY2020 · AI